BioAge Labs, Inc. (BIOA): Total Liabilities
$22.84M
As of 2025-12-31
$22.02M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.84M | -34.9% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $35.11M | -47.3% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $66.60M | n/a | 2025-03-20, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $22.84M | -34.9% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.58M | -4.7% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $134.59M | +71.4% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $46.33M | -23.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $44.74M | +15.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $141.50M | +146.0% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
Compare BIOA, ISCO, PGEN, PRTA side by side · Screen every company in Pharmaceutical Preparations ↗